Gary Nabel

ModeX Therapeutics, President and CEO
OPKO Health, Chief Innovation Officer and Board Director

Dr. Gary Nabel co-founded ModeX Therapeutics and is President and CEO. Dr. Nabel started his academic career at the Howard Hughes Medical Institute at the University of Michigan. He then joined the National Institutes of Health and became the founding Director of the Vaccine Research Center, pioneering a renaissance in vaccine development and providing overall direction and scientific leadership of basic, clinical and translational research activities as well as guiding development of novel vaccine strategies. Dr. Nabel was Chief Scientific Officer at Sanofi from 2012 to 2020 where he provided scientific oversight of Sanofi’s research portfolio, guiding numerous projects into clinical development and eventual registration. During his tenure at Sanofi, he led the Breakthrough Laboratory where he developed the first trispecific antibody now in development for HIV.

Dr. Nabel is a member of the National Academy of Medicine, an elected fellow of the Association of American Physicians, the American Academy of the Arts and Sciences, the American Society of Clinical Investigation, and the American Association for the Advancement of Sciences. He has received many awards and honors, including the U.S. Army Medical Department’s Order of Military Medical Merit as well as the Amgen Scientific Achievement Award from the American Society for Biochemistry and Molecular Biology. He acted as the Chair of the Board for the Keystone Scientific Symposia from 2017 to 2019, and as the Editor for the Journal of Virology from 1995-2005. He is a member of the board of SIGA Technologies and Candel Therapeutics, and the scientific advisory board of the Coalition of Epidemic Preparedness Innovations (CEPI).

Dr. Nabel also serves as Chief Innovation Officer of OPKO Health, and is a director of the Board.

OPKO Leadership